🇺🇸 FDA
Pipeline program

Enzalutamide

EudraCT Number: 2014-001162-10

Phase 2 small_molecule completed

Quick answer

Enzalutamide for Prostate Cancer Metastatic is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Prostate Cancer Metastatic
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials